Faculté de Médecine
1, rue Gaston Veil
158 articles about OSE Immunotherapeutics
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
AbbVie Inc. and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.
AbbVie continued its dealmaking spree Wednesday by partnering with OSE Immunotherapeutics to develop its early-stage, first-in-class antibody for chronic and severe inflammation.
OSE Immunotherapeutics SA updates on its clinical portfolio advancements and provides 2024 outlook.
OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
OSE Immunotherapeutics SA presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, MA.
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key milestones achieved during H1 2023 as well as the Company’s outlook for its immunotherapies in immuno-oncology and immuno-inflammation.
OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the peer-reviewed publication in Annals of Oncology* of the randomized Phase 3 clinical trial (Atalante-1**) on T-cell epitope cancer vaccine Tedopi® in HLA-A2 positive patients with advanced or metastatic NSCLC in monotherapy in third line NSCLC with secondary resistance to immune checkpoint inhibitors (ICI).
OSE Immunotherapeutics SA announced that the trial’s Independent Drug Safety Monitoring Board provided a positive recommendation on the continuation until its completion of the Phase 2 clinical trial of IL-7 Receptor antagonist Lusvertikimab in ulcerative colitis.
OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
OSE Immunotherapeutics SA announced that the United States Patent and Trademark Office has granted a new patent protecting Tedopi®, a therapeutic cancer vaccine treating HLA-A2 positive patients after secondary resistance to PD-1/PD-L1 immune checkpoint inhibitor treatment.
OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences
OSE Immunotherapeutics SA presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics Europe 2023 Conference in Amsterdam, Netherlands, at the FOCIS 2023 Annual Meeting, the 4th Annual Cytokine-Based Drug Development Summit 2023 and at the 3rd Annual Tumor Myeloid-directed Therapies Summit 2023 in Boston, US.
OSE Immunotherapeutics SA presented a poster and a publication in abstract book featuring Tedopi®, an immunotherapy activating tumor specific T-cells, in non-small cell lung cancer and in ovarian cancer at the 2023 American Society of Clinical Oncology Annual Meeting held June 2 - 6.
OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2022 and provided an update on key clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2023 Company’s outlook.
OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology
OSE Immunotherapeutics SA presented two additional posters reporting the latest research updates on CLEC-1, from its Myeloid platform, at the 2023 American Association for Cancer Research Annual Meeting held in Orlando on April 14-19.
OSE Immunotherapeutics SA announces three presentations at the American Association for Cancer Research Annual Meeting in Orlando, April 14-19, 2023.
OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating tumor specific T-cells, in phase 3 in monotherapy in advanced or metastatic non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (ICI).
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately.
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.
OSE Immunotherapeutics SA announces that the Company is one of the first biotech startup companies selected by Microsoft France to be a privileged partner of its support program for French Biotech & Deeptech Startups.
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the appointment of six leading international experts to its newly formed Scientific Advisory Board (SAB) to guide the Company in its next phases of growth and scientific orientations.
OSE Immunotherapeutics SA and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation, presented four posters featuring neoepitope specific immunotherapy Tedopi® in various cancer indications at the American Society of Clinical Oncology Annual Meeting held June 4 – 7.
OSE Immunotherapeutics Announces Four Poster Presentations of Neoepitope Combination Tedopi® in Immuno-Oncology at ASCO 2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring neoepitope combination Tedopi® in various cancer indications at the American Society of Clinical Oncology (ASCO) Annual Meeting.